missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human SERPINB4 (aa 256-284) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (55%), Rat (55%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-62118 (PA5-62118. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
SERPINB4 is also called squamous cell carcinoma antigen 2 (SCCA-2) or leupin. It directly inhibits human granzyme proteolytic activity and that overexpression of SERPINB4 in HeLa cells inhibits recombinant granzyme-induced as well as NK cell-mediated cell death.
Specifications
Specifications
| Accession Number | P48594 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 6318 |
| Name | Human SERPINB4 (aa 256-284) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 1110001H02Rik; 1110013A16Rik; LEUPIN; Leupin SERPINB4; Peptidase inhibitor 11; PI11; PI-11; protease inhibitor (leucine-serpin); RGD1562868; SCCA1; SCCA2; SCCA-2; SCCA2/SCCA1 fusion protein; serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 3 A; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3 A; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 4; serine peptidase inhibitor, clade B, member 3 A; serpin B4; serpin family B member 4; serpin peptidase inhibitor, clade B (ovalbumin), member 4; Serpinb3a; SERPINB4; Sqn5; squamous cell carcinoma antigen 1; squamous cell carcinoma antigen 2 |
| Common Name | SERPINB4 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction